Myriad Genetics Inc
MYGN
NASDAQ
Biotechnology
$3.03
USD
-0.14 (-4.42%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $307.03M
Volume 1.6M
About Myriad Genetics Inc
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
CEO
Mr. Samraat Raha
HQ
Salt Lake City, UTAH, US
Founded
1995
Employees
2,700
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on MYGN.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
-3.2%
-7.0 pp
Gross Margin (TTM)
68.8%
-1.6 pp
Operating Margin (TTM)
-12.2%
+37.9 pp
Net Margin (TTM)
-14.0%
+33.5 pp
ROE (TTM)
-37.1%
+64.8 pp
Free Cash Flow (TTM)
$-7.30M
—
Financial Snapshot
Revenue
$806.60M
-3.2%
YoY
Gross Margin
69%
TTM
-2.3%
YoY
Net Income
$-112.60M
+71.5%
YoY
Operating Cash Flow
$7.70M
+134.1%
YoY
Key Statistics
Open
$3.17
Previous Close
$3.17
Day Range
$3.01 - $3.18
52 Week Range
$2.74 - $8.59
Volume
1.6M
Average Volume (10 Days)
4.0M
Dividend Yield
—
Valuation Measurement
Market Cap
$307.03M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
0.38
Price / Book
1.01
Financial Highlights
Profit Margin
-14.0%
Return on Assets
-17.6%
Return on Equity
-37.1%
Revenue (TTM)
$806.60M
Net Income (TTM)
$-112.60M
Diluted EPS (TTM)
-$1.19
Total Cash (MRQ)
$115.20M
Levered FCF (TTM)
$-7.30M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Similar Stocks
SION
Sionna Therapeutics Inc
$6.46
▼ -1.2%
AVXL
Anavex Life Sciences Corp
$3.22
▼ -1.5%
FATE
Fate Therapeutics Inc
$2.57
▲ +2.0%
ANIK
Anika Therapeutics Inc
$21.50
▲ +1.6%
SRZN
Surrozen Inc
$23.96
▲ +1.0%
TRDA
Entrada Therapeutics Inc
$7.46
▲ +0.1%
ALXO
ALX Oncology Holdings Inc
$1.96
▲ +1.0%
ZSQR
Z Squared Inc (Delaware)
$3.94
▼ -5.3%
ELDN
Eledon Pharmaceuticals Inc
$3.54
▼ -4.3%
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 02
Est. EPS
Adjusted consensus estimate
-$0.17